The literary review consists of two parts. The first takes into consideration the renewed European guidelines of 2016 for atrial fibrillation patients management. The accent is made on the renewed approaches for anticoagulation treatment regardless the gender, on new points in the risks of haemorrhagic complications, renewed schemes of double and triple antithrombotic therapy after the percutaneous intervention and/or acute coronary syndrome and approaches for the restarting of anticoagulation after ischemic stroke. The second part focuses on the real clinical practice including three latest publications, which consider the safety of warfarin, dabigatran and rivaroxaban in patients with atrial fibrillation of non-valvular aetiology by the data from insurance companies. Based on the data provided, there is a conclusion on the benefit of dabigatran for more safety in all recommended dosages.
Napalkov, D. A., & Sokolova, A. A. (2016). Management of patient with arterial fibrillation: What’s new? Russian Journal of Cardiology, 140(12), 97–102. https://doi.org/10.15829/1560-4071-2016-12-97-102